Allogeneic

Are stable producer cells the future of viral vector manufacturing and when will allogeneic cell therapy take hold?

30-Nov-2020 By Jane Byrne

From operational uncertainty and outdated manual processes to new cell lines and a potential shift towards allogeneic cell therapy, CRB’s new report - Horizons: Cell and Gene Therapy - finds the biopharma industry at the critical intersection of obstacle...

Consolidation continues as Catalent lays down $330m for MaSTherCell

05-Feb-2020 By Ben Hargreaves

Catalent provides another example of the trend by bigger CDMO to snatch up smaller cell and gene therapy specialists.

Mesoblast and Lonza agree commercial manufacture of allogeneic cell therapy

22-Oct-2019 By Ben Hargreaves

Lonza will manufacture mesoblast’s lead cell therapy ahead of a planned US market launch, which could occur next year.

Grünenthal sets down over $1bn for off-the-shelf cell therapy

12-Sep-2019 By Ben Hargreaves

Grünenthal agrees deal with Mesoblast to develop and commercialize an allogeneic cell therapy for chronic lower back pain.